FY2022 EPS Estimates for Trevena, Inc. (NASDAQ:TRVN) Decreased by Analyst

Trevena, Inc. (NASDAQ:TRVNGet Rating) – Investment analysts at HC Wainwright dropped their FY2022 earnings estimates for shares of Trevena in a report released on Tuesday, November 22nd. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($8.64) per share for the year, down from their previous forecast of ($8.25). The consensus estimate for Trevena’s current full-year earnings is ($8.67) per share. HC Wainwright also issued estimates for Trevena’s Q4 2022 earnings at ($1.73) EPS, Q1 2023 earnings at ($1.69) EPS, Q2 2023 earnings at ($0.96) EPS, Q3 2023 earnings at ($0.92) EPS, Q4 2023 earnings at ($0.89) EPS, FY2023 earnings at ($4.21) EPS, FY2024 earnings at ($1.62) EPS, FY2025 earnings at ($0.12) EPS and FY2026 earnings at $1.02 EPS.

Separately, StockNews.com started coverage on shares of Trevena in a research note on Wednesday. They issued a “sell” rating for the company.

Trevena Price Performance

Shares of Trevena stock opened at $3.46 on Thursday. Trevena has a twelve month low of $2.38 and a twelve month high of $19.00. The company has a quick ratio of 4.51, a current ratio of 4.60 and a debt-to-equity ratio of 0.61. The company has a 50-day simple moving average of $0.87 and a two-hundred day simple moving average of $0.50. The stock has a market capitalization of $24.05 million, a price-to-earnings ratio of -0.38 and a beta of 1.86.

Institutional Trading of Trevena

Several hedge funds and other institutional investors have recently bought and sold shares of TRVN. GSA Capital Partners LLP acquired a new position in shares of Trevena in the 1st quarter valued at approximately $471,000. Renaissance Technologies LLC raised its position in shares of Trevena by 90.8% in the 1st quarter. Renaissance Technologies LLC now owns 308,400 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 146,800 shares in the last quarter. Captrust Financial Advisors raised its position in shares of Trevena by 10,526.3% in the 1st quarter. Captrust Financial Advisors now owns 201,900 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 200,000 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its position in shares of Trevena by 133.3% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 65,858 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 37,633 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Trevena in the 2nd quarter valued at approximately $51,000. Institutional investors and hedge funds own 12.34% of the company’s stock.

About Trevena

(Get Rating)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Articles

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.